Topic
Clinical Trials
Topic counter · /clinical trials
Clinical Trials
10 pieces on this counter
· 2 min
Dupixent Improved Quality of Life in Chronic Hives Trials, Analysis Shows
Pooled phase 3 data presented at EADV 2026 found Dupixent improved hives-specific quality of life, with 74.3% free of bothersome eye and lip swelling versus 60…
· 3 min
Two-Year Data: Psoriasis Pill Kept Skin 90% Clearer in 72% of Patients
ICOTYDE kept skin at least 90 percent clearer in 72 percent of patients through week 112. Complete clearance hit 44 percent, with no new safety concerns.
· 2 min
ZORYVE Improved Sex Lives in Genital Psoriasis Trials
ZORYVE (roflumilast) beat vehicle on sexual difficulties, itch and quality of life in genital psoriasis subgroups across three phase 3 trials, 2026 conference…
· 3 min
Zero Skin Flares in 228 Patients Switching From Dupixent to Rinvoq
Zero of 228 patients flared within 16 weeks of switching from DUPIXENT to RINVOQ, per an analysis presented at the 2026 Fall Clinical Dermatology Conference.
· 3 min
Oral JAK Inhibitor Brepocitinib Enters Phase 2/3 Trial for Scarring Alopecia
A phase 2/3 trial will test oral JAK inhibitor brepocitinib in moderate to severe lichen planopilaris, which could become the first FDA-approved systemic thera…
· 2 min
Cosmo's Clascoterone Posts Strong 12-Month Hair Loss Data
Clascoterone 5% solution delivered 2.39-fold greater hair count improvement at 12 months. Cosmo will file for FDA approval in early 2027, the first new mechani…
· 3 min
Avalo's Monthly HS Injection Clears Phase 2 With 43% Response Rate
Avalo's abdakibart hit a 43 percent HiSCR75 response in phase 2 for hidradenitis suppurativa, roughly 17 points above placebo, with a once-monthly dosing optio…
· 2 min
FDA Clears Phase 2a Trial of Dual-Target Antibody NAV-240 for HS
Navigator Medicines has begun dosing patients in an FDA-cleared phase 2a trial of NAV-240, a dual-target antibody blocking TNF and O40L in moderate to severe H…
· 2 min
Ruxolitinib Cream Hit 79% Response Rate in HS Phase 2 Trial
A phase 2 trial found ruxolitinib 1.5% cream (Opzelura) produced a 79% response rate in mild to moderate hidradenitis suppurativa. Phase 3 trials are now under…
· 2 min
Bempikibart Cut Hair Loss Scores 35.3% in Alopecia Areata Trial
Q32 Bio's bempikibart cut SALT hair-loss scores by 35.3 percent at week 36, with 40 percent of severe alopecia areata patients reaching SALT-20 — even after fa…
